TY  - JOUR
AU  - Dao Trong, P.
AU  - Gluszak, M.
AU  - Reuss, D.
AU  - von Deimling, Andreas
AU  - Wick, A.
AU  - König, L.
AU  - Debus, J.
AU  - Herold-Mende, C.
AU  - Unterberg, A.
AU  - Jungk, C.
TI  - Isocitrate-dehydrogenase-mutant lower grade glioma in elderly patients: treatment and outcome in a molecularly characterized contemporary cohort.
JO  - Journal of neuro-oncology
VL  - 161
IS  - 3
SN  - 0167-594x
CY  - Dordrecht [u.a.]
PB  - Springer Science + Business Media B.V
M1  - DKFZ-2023-00108
SP  - 605-615
PY  - 2023
N1  - 2023 Feb;161(3):605-615
AB  - Lower-grade glioma (LGG) is rare among patients above the age of 60 ('elderly'). Previous studies reported poor outcome, likely due to the inclusion of isocitrate dehydrogenase (IDH) wildtype astrocytomas and advocated defensive surgical and adjuvant treatment. This study set out to question this paradigm analyzing a contemporary cohort of patients with IDH mutant astrocytoma and oligodendroglioma WHO grade 2 and 3.Elderly patients treated in our department for a supratentorial, hemispheric LGG between 2009 and 2019 were retrospectively analyzed for patient-, tumor- and treatment-related factors and progression-free survival (PFS) and compared to patients aged under 60. Inclusion required the availability of subtype-defining molecular data and pre- and post-operative tumor volumes.207 patients were included, among those 21 elderlies (10
KW  - Elderly (Other)
KW  - Isocitrate dehydrogenase mutant glioma (Other)
KW  - Lower grade glioma (Other)
KW  - WHO classification (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:36648586
DO  - DOI:10.1007/s11060-022-04230-1
UR  - https://inrepo02.dkfz.de/record/186780
ER  -